Chemical Property of Glucagon-like peptide 1
Chemical Property:
- XLogP3:-14.2
- Hydrogen Bond Donor Count:49
- Hydrogen Bond Acceptor Count:50
- Rotatable Bond Count:109
- Exact Mass:3296.6659301
- Heavy Atom Count:234
- Complexity:7660
- Purity/Quality:
-
99%, *data from raw suppliers
Glucagon-like Peptide 1 *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
- Canonical SMILES:CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N
- Isomeric SMILES:CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
- Recent ClinicalTrials:Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments
- Recent EU Clinical Trials:A phase II study to investigate the protective effects of Glucagon--like Peptide--1 (GLP--1) in patients undergoing elective angioplasty and stenting.
-
Description
GLP-1 stimulates pancreatic β cells to secrete insulin as
an incretin hormone. GLP-1 also has additional actions,
including suppression of glucagon secretion, inhibition of
gastric motility, and promotion of satiety. GLP-1 was first identified in the early 1980s, following
the cloning of the proglucagon gene. The biological activity of GLP-1 was investigated initially by using the
N-terminal extended forms of GLP-1(1–37 and 1–36
amide). However, these forms were devoid of biological
activity. In the late 1980s, bioactive GLP-1 peptides were
purified from gut extracts and were identified to be GLP-1(7–37) and GLP-1(7–36)-amide. In the current literature,
the unqualified designation of GLP-1 corresponds to the
truncated peptides.
-
Biological Functions
Glucagon-like peptide-1 (GLP-1) is an incretin, a natural peptide hormone secreted in response to food intake. Incretins
have multiple physiological effects to lower blood sugar, including the stimulation of insulin release and the inhibition of
glucagon release following meals.
-
Clinical Use
GLP-1 enhances glucose-stimulated insulin release.
GLP-1 agonists are resistant to degradation by DPP-4;
thus these agonists are used clinically for the treatment
of diabetes. DPP-4 inhibitors are also acceptable for use
in diabetes patients because GLP-1 is rapidly deactivated
by DPP-4.
